t
ANGLE plc announced its name change to CelLBxHealth plc has been registered at Companies House. The company's name and TIDM, now CLBX, became effective on the London Stock Exchange from 8.00 a.m. on 29 October 2025. Concurrently, the company's website address will change to CelLBxHealth.com, also effective from 8.00 a.m. on 29 October 2025.
29 October 2025
ANGLE plc ("the Company")
Change of Name
Further to the announcement on 8 October 2025, ANGLE plc announces that the application to change the name of the Company to CelLBxHealth plc has now been registered at Companies House.
Accordingly, the Company's change of name and change of TIDM to CLBX will be effective on the London Stock Exchange plc from 8.00 a.m. on 29 October 2025. The Company's ISIN and SEDOL remain unchanged.
In conjunction with the name change, the Company's website address will change to CelLBxHealth.com. All information required by AIM Rule 26 will be located on the "Investors" section of the angleplc.com website with effect from 8.00 a.m. on 29 October 2025.
Shareholders' rights are unaffected by the change and existing share certificates should be retained and remain valid.
For further information:
|
CelLBxHealth |
+44 (0) 1483 343434 |
|
Dr Jan Groen, Executive Chairman Peter Collins, Interim CEO |
|
|
Cavendish (NOMAD and Broker) Geoff Nash / Isaac Hooper/ Hamza Munshi (Corporate Finance) Sunila de Silva (Corporate Broking) Nigel Birks (Life Science Specialist Sales) |
+44 (0) 20 7220 0500 |
|
FTI Consulting Simon Conway, Ciara Martin, Sam Purewal Matthew Ventimiglia (US) |
+44 (0) 203 727 1000 +1 (212) 850 5624 |
Notes for editors
About CelLBxHealth plc
CelLBxHealth plc is a global precision CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs from blood and can be seamlessly integrated with existing laboratory instruments for comprehensive downstream analysis including whole-cell imaging, proteomic profiling and full genomic workflows.
Commercial activities focus on (1) Product Sales: Accelerating Parsortix platform adoption and consumable sales through CROs and clinical lab partnerships. (2) Lab Developed Tests (LDTs): Strategic partnerships combined with a focused in-house development programme (3) Laboratory services: Clinical trial support and assay development.
The product portfolio comprises the Parsortix® platform with associated consumables and assays. Laboratory services are delivered from the Company's GLP certified UK laboratory, providing bespoke clinical-trial support and assay development.